Clinical Disorder Treatment Market Trends

Growth Drivers

• Treatment advances: The innovations in terms of treatment approaches, including the development of personalized medicine, digital therapeutics, and new pharmacological drugs, are readily driving business in the clinical disorder treatment market. In September 2024, Bristol Myers Squibb announced that its COBENFY (xanomeline and trospium chloride) had been accepted by the U.S. FDA as a first-in-class oral treatment for schizophrenia in adults, which offers a novel mechanism targeting M1 and M4 receptors without blocking D2 receptors.
• Increasing healthcare expenditures: Both the government and private entities are readily making investments in the mental health infrastructure, research, and service delivery. Also, the policy initiatives aimed at integrating mental health into primary care support market expansion. Testifying to this, the NIH in August 2022 stated that the median proportion of government health expenditure allocated to mental health services across 78 countries was 2.7%, with significant variation ranging from as low as 0.1% in Zimbabwe to 12.9% in France, hence suitable for standard market growth.
• Emergence of telemedicine & remote care: The ever-increasing adoption of telemedicine and remote care has evidently reshaped the foundation of clinical disorder treatments market in recent years. This can be testified from a WHO article published in March 2025 stating it had launched a 13-part webinar series called Telemedicine in Action, in collaboration with Intelehealth, thereby promoting equitable healthcare access through telemedicine in developing countries, thereby positively influencing market growth.

Historic Trends in Global Prevalence and Impact of Common Mental Disorders 2019

Source: WHO

International Comparison of Health Expenditure, 2023

Source: OECD

Key Advances in Clinical Disorder Treatment Market: Anxiety and Schizophrenia (2023-2025)

Source: Company Official Press Releases

Challenges

• High research & development expenses: The costs associated with research and development in the clinical disorder treatment market are relatively higher, making it challenging for niche manufacturers. Also, the development of new treatments for clinical disorders, especially rare or complex conditions, requires a huge investment in research and clinical trials.  Therefore, this process can be extremely time-consuming and often faces high failure rates, making it costly and risky for firms.
• Regulatory approval delays: This is yet another factor negatively influencing the growth of the clinical disorder treatment market across most nations. The market is heavily regulated to ensure safety and efficacy, navigating through which can be complicated and time-consuming as well. Hence, these strict requirements and varying standards across countries can delay product launches and sometimes limit patient access to efficacious treatments.